

Kiyoto Tsuchiya

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6335602/publications.pdf>

Version: 2024-02-01

40
papers

1,301
citations

430754

18
h-index

360920

35
g-index

42
all docs

42
docs citations

42
times ranked

1753
citing authors

#	ARTICLE	IF	CITATIONS
1	Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. <i>Biochemical and Biophysical Research Communications</i> , 2004, 319, 1322-1326.	1.0	257
2	Successful Efavirenz Dose Reduction in HIV Type 1-Infected Individuals with Cytochrome P450 2B6 *6 and *26. <i>Clinical Infectious Diseases</i> , 2007, 45, 1230-1237.	2.9	210
3	Single Nucleotide Polymorphisms in ABCC2 Associate With Tenofovir-Induced Kidney Tubular Dysfunction in Japanese Patients With HIV-1 Infection: A Pharmacogenetic Study. <i>Clinical Infectious Diseases</i> , 2012, 55, 1558-1567.	2.9	72
4	Serum CCL17 level becomes a predictive marker to distinguish between mild/moderate and severe/critical disease in patients with COVID-19. <i>Gene</i> , 2021, 766, 145145.	1.0	68
5	Involvement of the Second Extracellular Loop and Transmembrane Residues of CCR5 in Inhibitor Binding and HIV-1 Fusion: Insights into the Mechanism of Allosteric Inhibition. <i>Journal of Molecular Biology</i> , 2008, 381, 956-974.	2.0	59
6	Correlates of neutralizing/SARS-CoV-2-S1-binding antibody response with adverse effects and immune kinetics in BNT162b2-vaccinated individuals. <i>Scientific Reports</i> , 2021, 11, 22848.	1.6	57
7	Role of P-glycoprotein in the efflux of raltegravir from human intestinal cells and CD4+ T-cells as an interaction target for anti-HIV agents. <i>Biochemical and Biophysical Research Communications</i> , 2013, 439, 221-227.	1.0	45
8	Emergence of Protease Inhibitor Resistance-Associated Mutations in Plasma HIV-1 Precedes That in Proviruses of Peripheral Blood Mononuclear Cells by More Than a Year. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2003, 34, 1-6.	0.9	43
9	Neutralization of SARS-CoV-2 with IgG from COVID-19-convalescent plasma. <i>Scientific Reports</i> , 2021, 11, 5563.	1.6	42
10	Combination of a Latency-Reversing Agent With a Smac Mimetic Minimizes Secondary HIV-1 Infection in vitro. <i>Frontiers in Microbiology</i> , 2018, 9, 2022.	1.5	39
11	Benzolactam-related compounds promote apoptosis of HIV-infected human cells via protein kinase C α -induced HIV latency reversal. <i>Journal of Biological Chemistry</i> , 2019, 294, 116-129.	1.6	31
12	Simultaneous determination of six HIV protease inhibitors (amprenavir, indinavir, lopinavir, nelfinavir,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf transcriptase inhibitor (efavirenz) in human plasma by high-performance liquid chromatography. <i>Biomedical Chromatography</i> , 2006, 20, 28-36.	0.8	29
13	Sphingomyelin Synthase 2, but Not Sphingomyelin Synthase 1, Is Involved in HIV-1 Envelope-mediated Membrane Fusion. <i>Journal of Biological Chemistry</i> , 2014, 289, 30842-30856.	1.6	26
14	Assessment of HIV prevalence among MSM in Tokyo using self-collected dried blood spots delivered through the postal service. <i>BMC Infectious Diseases</i> , 2018, 18, 627.	1.3	25
15	Naturally Selected Rilpivirine-Resistant HIV-1 Variants by Host Cellular Immunity. <i>Clinical Infectious Diseases</i> , 2013, 57, 1051-1055.	2.9	22
16	Lifelong Prophylaxis With Trimethoprim-Sulfamethoxazole for Prevention of Outbreak of <i>Pneumocystis jirovecii</i> Pneumonia in Kidney Transplant Recipients. <i>Transplantation Direct</i> , 2017, 3, e151.	0.8	21
17	High plasma concentrations of dolutegravir in patients with ABCG2 genetic variants. <i>Pharmacogenetics and Genomics</i> , 2017, 27, 416-419.	0.7	21
18	High-risk status of HIV-1 infection in the very low epidemic country, Mongolia, 2007. <i>International Journal of STD and AIDS</i> , 2009, 20, 391-394.	0.5	18

#	ARTICLE	IF	CITATIONS
19	Arginine insertion and loss of N-linked glycosylation site in HIV-1 envelope V3 region confer CXCR4-tropism. <i>Scientific Reports</i> , 2013, 3, 2389.	1.6	18
20	Allele and Genotype Frequencies of <i>Cytochrome P450 2B6</i> Gene in a Mongolian Population. <i>Drug Metabolism and Disposition</i> , 2009, 37, 1991-1993.	1.7	17
21	High-performance liquid chromatography-tandem mass spectrometry for simultaneous determination of raltegravir, dolutegravir and elvitegravir concentrations in human plasma and cerebrospinal fluid samples. <i>Biomedical Chromatography</i> , 2018, 32, e4058.	0.8	16
22	Single-nucleotide polymorphisms in the UDP-glucuronosyltransferase 1A-3' untranslated region are associated with atazanavir-induced nephrolithiasis in patients with HIV-1 infection: a pharmacogenetic study. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 3320-3328.	1.3	15
23	Low Raltegravir Concentration in Cerebrospinal Fluid in Patients With ABCG2 Genetic Variants. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2014, 66, 484-486.	0.9	14
24	Brief Report. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2016, 72, 11-14.	0.9	14
25	Accumulation of lopinavir resistance-associated mutations over 3 years follow-up of patients on highly active antiretroviral therapy: implication in salvage therapy. <i>Aids</i> , 2001, 15, 1183-1184.	1.0	14
26	Identification of a Current Hot Spot of HIV Type 1 Transmission in Mongolia by Molecular Epidemiological Analysis. <i>AIDS Research and Human Retroviruses</i> , 2011, 27, 1073-1080.	0.5	11
27	Emergence of CXCR4-tropic HIV-1 variants followed by rapid disease progression in hemophiliac slow progressors. <i>PLoS ONE</i> , 2017, 12, e0177033.	1.1	10
28	Isolation and Molecular Characterization of a Nelfinavir (NFV)-Resistant Human Immunodeficiency Virus Type 1 That Exhibits NFV-Dependent Enhancement of Replication. <i>Journal of Virology</i> , 2003, 77, 318-327.	1.5	9
29	Protein Arginine N-methyltransferases 5 and 7 Promote HIV-1 Production. <i>Viruses</i> , 2020, 12, 355.	1.5	9
30	Asymptomatic COVID-19 re-infection in a Japanese male by elevated half-maximal inhibitory concentration (IC50) of neutralizing antibodies. <i>Journal of Infection and Chemotherapy</i> , 2021, 27, 1063-1067.	0.8	9
31	A widely distributed HIV-1 provirus elimination assay to evaluate latency-reversing agents in vitro. <i>Cell Reports Methods</i> , 2021, 1, 100122.	1.4	9
32	Full-Genome Analysis of Hepatitis C Virus in Japanese and Non-Japanese Patients Coinfected With HIV-1 in Tokyo. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2019, 80, 350-357.	0.9	8
33	The second molecular epidemiological study of HIV infection in Mongolia between 2010 and 2016. <i>PLoS ONE</i> , 2017, 12, e0189605.	1.1	7
34	“All-in-One Assay”, a direct phenotypic anti-human immunodeficiency virus type 1 drug resistance assay for three-drug combination therapies that takes into consideration in vivo drug concentrations. <i>Journal of Virological Methods</i> , 2003, 111, 43-53.	1.0	6
35	Rilpivirine resistance mutation E138K in HIV-1 reverse transcriptase predisposed by prevalent polymorphic mutations. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2760-2766.	1.3	6
36	A Therapeutic Strategy to Combat HIV-1 Latently Infected Cells With a Combination of Latency-Reversing Agents Containing DAG-Lactone PKC Activators. <i>Frontiers in Microbiology</i> , 2021, 12, 636276.	1.5	6

#	ARTICLE	IF	CITATIONS
37	<i>N</i> -(4-Hydroxyphenyl) Retinamide Suppresses SARS-CoV-2 Spike Protein-Mediated Cell-Cell Fusion by a Dihydroceramide 1 ⁴ -Desaturase 1-Independent Mechanism. <i>Journal of Virology</i> , 2021, 95, e0080721.	1.5	6
38	Primary nelfinavir (NFV)-associated resistance mutations during a follow-up period of 108 weeks in protease inhibitor naïve patients treated with NFV-containing regimens in an HIV clinic cohort. <i>Journal of Clinical Virology</i> , 2003, 27, 252-262.	1.6	2
39	Full-genome analysis of hepatitis C virus in HIV-coinfected hemophiliac Japanese patients. <i>Hepatology Research</i> , 2020, 50, 763-769.	1.8	1
40	A Widely-Distributed Hiv-1 Provirus Elimination Assay to Evaluate Latency-Reversing Agents in Vitro. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0